venBio Partners LLC
CIK 1776382 · View on SEC EDGAR ↗
- Portfolio value
- $519.4M
- Positions
- 7
- As of
- June 30, 2026
Portfolio value QoQ: +85.1% 13F does not disclose cash
- Top 10 holdings weight
- 100.00%
- Top 25 holdings weight
- 100.00%
- Positions above 1%
- 6
- Effective number of positions
- 4.1
Based on 13F long-equity holdings only (cash, bonds, shorts not disclosed)
Turnover Q2 2026: 1.01% Est. buys $182,915,296 · sells $4,040,780
Median holding: 5.5 quarters Tracked Q4 2024–Q2 2026 · 70.0% still held
- New positions
- 2
- Increased
- 1
- Decreased
- 1
- Closed
- 1
On this page
- Performance vs S&P How this manager's 13F portfolio performed against the S&P 500.
- Sector breakdown How the portfolio splits across market sectors.
- Portfolio Every stock this institution reports holding, from its latest 13F.
- Biggest new bets Brand-new positions opened in the latest quarter.
- Top moves The biggest position increases and decreases this quarter.
- Exited positions Positions the manager fully sold out of last quarter.
Performance vs S&P 500
Annualized: +59.5% · S&P 500: +18.0%
Approximates a buy-and-hold portfolio built from quarterly SEC 13F snapshots. Excludes cash, short positions, options/derivatives, and non-13(f) securities — reflects the disclosed long-equity book only, not total fund AUM. SEC filing lag is up to 45 days; this is not a real-time-copyable timing.
Priceable coverage: 97.3% · Options excluded: 0.0%
Sector breakdown
Full portfolio 7 positions
| Type | Streak | 8Q trend | |||||
|---|---|---|---|---|---|---|---|
| PHVS Pharvaris N.V. - Ordinary Shares | $160,569,809 | 30.92% | 4,643,430 | $29,509,471 | Up ×1 | ||
| Unknown issuer (CUSIP: 698955101) | $144,149,497 | 27.75% | 5,266,697 | Up ×1 | |||
| ALMS Alumis Inc. - Common Stock | $127,429,401 | 24.53% | 4,528,408 | $27,668,573 | |||
| ACHV Achieve Life Sciences, Inc. - Common Shares | $38,623,122 | 7.44% | 5,914,720 | Up ×1 | |||
| ALXO ALX Oncology Holdings Inc. - Common Stock | $26,671,201 | 5.14% | 12,884,638 | $837,502 | |||
| HRMY Harmony Biosciences Holdings, Inc. - Common Stock | $17,192,584 | 3.31% | 472,194 | $3,490,260 | Down ×1 | ||
| LYEL Lyell Immunopharma, Inc. - Common Stock | $4,744,643 | 0.91% | 337,697 | $-2,029,559 | |||
| No matches | |||||||
Biggest new bets
New positions opened this quarter, largest first.
| Security | Value | Shares | % of portfolio |
|---|---|---|---|
| Unknown issuer (CUSIP: 698955101) | $144,149,497 | 5,266,697 | 27.75% |
| ACHV | $38,623,122 | 5,914,720 | 7.44% |
Top movers (QoQ)
Exited positions
Includes corporate events (mergers, delistings) — not all exits are sells
Closed positions reflect 13F reporting changes; for index managers these are often mechanical (delisting, M&A, index rebalancing), not active decisions.
| Security | Quarter | Shares before | Value before | Price since exit |
|---|---|---|---|---|
| SLRN | June 30, 2025 | 3,806,410 | $9,401,833 | No longer tracked |
| LYELXXXX | June 30, 2025 | 7,102,190 | $3,820,978 | No longer tracked |
| ARTV | June 30, 2026 | 531,337 | $3,421,810 | 15.8% |